Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer.
Hannah Y ChenWeilu ZhaoShorook Na'araFrederico Omar Gleber-NettoTongxin XieShahrukh AliZachary M ThompsonJane BuellHaleigh StaffordPriyardhisini NagarajanMichael A DaviesMichael K WongMichael R MigdenPadmanee SharmaJeffrey N MyersNeil D GrossMoran AmitPublished in: JCO precision oncology (2023)
The effect of BBs on cancer survival outcomes is heterogeneous and varies according to cancer type and immunotherapy status. In this study, BB intake was associated with worse DSS and DFS in patients with head and neck cancer not treated with immunotherapy, but not in patients with NSCLC or skin cancer.